First Horizon Advisors Inc. raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 265,668 shares of the company's stock after acquiring an additional 12,601 shares during the period. Johnson & Johnson comprises 1.2% of First Horizon Advisors Inc.'s portfolio, making the stock its 11th biggest position. First Horizon Advisors Inc.'s holdings in Johnson & Johnson were worth $44,059,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on JNJ shares. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.
Check Out Our Latest Research Report on JNJ
Johnson & Johnson Trading Up 0.2%
Shares of Johnson & Johnson stock traded up $0.34 during midday trading on Friday, reaching $155.90. 3,482,521 shares of the company's stock traded hands, compared to its average volume of 8,047,072. The company has a market cap of $375.11 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The stock has a 50 day moving average of $153.68 and a 200-day moving average of $154.03. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More

Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.